Evidence map›Paper›PMID 28704392›Full record

ArticlePloS one2017

Redifferentiation of aged human articular chondrocytes by combining bone morphogenetic protein-2 and melanoma inhibitory activity protein in 3D-culture.

Stephan Payr, Brigitte Tichy, Clemens Atteneder, Marc Michel, Thomas Tiefenboeck, Nikolaus Lang, Sylvia Nuernberger, Stefan Hajdu, Elizabeth Rosado-Balmayor, Stefan Marlovits and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. BioMed research international · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Stephan PayrDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Brigitte TichyDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Clemens AttenederDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Marc MichelDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Thomas TiefenboeckDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Nikolaus LangDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Sylvia NuernbergerDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Stefan HajduDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Elizabeth Rosado-BalmayorDepartment of Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University Munich, Germany.
Stefan MarlovitsDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Christian AlbrechtDepartment of Trauma Surgery, General Hospital, Medical University of Vienna, Austria.
Austrian Cluster for Tissue Regeneration · ATMedical University of Vienna · ATVienna General Hospital · ATKlinikum rechts der Isar · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma inhibitory activity (MIA) affects the differentiation to hyaline cartilage and can inhibit the osteogenic potential of bone morphogenetic protein (BMP)-2 in mesenchymal stem cells (MSC). The aim of this study was to investigate if MIA also inhibits the osteogenic potential of BMP-2 in human articular chondrocytes during redifferentiation, which may lead to a higher grade of differentiation without calcification. HAC of four female patients (mean age: 73.75 ±6.98) were seeded into 3D culture for 28 days; after adding the recombinant proteins, four groups were formed (Control, BMP-2, MIA, BMP-2+MIA). Samples were analysed for gene expression, glycosaminoglycan (GAG) content and histology on day 0, 14 and 28. Collagen type 2 (COL2A1) was significantly increased in the BMP-2 containing groups on day 28; BMP-2 (100-fold, p = 0.001), BMP-2+MIA (65-fold, p = 0.009) and similar to the level of native cartilage. Higher aggrecan (Agg) levels were present in the BMP-2 (3-fold, p = 0.007) and BMP-2+MIA (4-fold, p = 0.002) group after 14 days and in the BMP-2 (9-fold, p = 0.001) group after 28 days. Collagen type 10 (COL10A1) was increased in the BMP-2 containing groups (6-fold, p = 0.006) but these levels were significantly below native cartilage. Alkaline phosphatase (ALP), collagen type 1 (COL1A1) and the glycosaminoglycan (GAG) content did not reveal any relevant differences between groups. BMP-2 is a potent inducer for differentiation of HAC. A significant enhancement of this effect in combination with MIA could not be observed. Furthermore no significant reduction of osteogenic markers during re-differentiation of chondrocytes was present combining BMP-2 and MIA.

Indexed as

AgedAged, 80 and overBone Morphogenetic Protein 2Cell Culture TechniquesCell DifferentiationCells, CulturedChondrocytesCollagen Type IIExtracellular Matrix ProteinsFemaleGene Expression ProfilingGene Expression RegulationGlycosaminoglycansHumansBone Morphogenetic Protein 2Collagen Type IIExtracellular Matrix ProteinsGlycosaminoglycans

Identifiers

PMID28704392
PMCPMC5509113
OpenAlexW2735749482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.